Medical News

RSS

ENMD-2076 demonstrates antitumor activity against murine xenograft models of CRC: Study

EntreMed, Inc., today announced the publication of preclinical results for its clinical-stage Aurora A/angiogenic kinase inhibitor, ENMD-2076, in human colorectal cancer xenograft models. The results of the study, conducted by EntreMed collaborators at the University of Colorado School of Medicine, were published in the June 1, 2010 issue of Clinical Cancer Research (Vol. 16, Issue 11).

2 Jun 2010

Biomoda, Obio sign MOU to establish CLIA-certified clinical laboratory in Ohio

Cancer diagnostics company Biomoda, Inc. and Obio, a corporation formed to pursue public and private funding for cancer research in Ohio, signed a memorandum of understanding to establish a CLIA-certified Biomoda clinical laboratory in Ohio to support ongoing research and development on Biomoda's porphyrin-based assay for the detection of early-stage cancer.

2 Jun 2010

Asuragen obtains license to integrate BRAF V600E mutation sequence into its molecular diagnostic products

Asuragen, Inc., a leader in molecular diagnostics and RNA-based pharmacogenomics services, announced today that it has obtained a non-exclusive license to incorporate the BRAF V600E mutation sequence into Asuragen's molecular diagnostic products. The license was obtained from Johns Hopkins University and includes the use of the BRAF V600E mutation as a component of diagnostic test kits and for use in Asuragen's CLIA laboratory for clinical research and patient testing.

2 Jun 2010

Constellation Pharmaceuticals raises $22 million in Series B financing round

Constellation Pharmaceuticals, Inc., the leading biopharmaceutical company focused on discovering and developing new drugs targeting epigenetic regulation of the human genome, today announced that it has raised $22 million in a Series B financing round.

2 Jun 2010

CDC data shows frequent binge drinkers more likely to report suboptimal self-rated health

Recent data from the Centers for Disease Control and Prevention show that excessive drinking is responsible for approximately 79,000 deaths annually in the United States. Binge drinking accounts for more than half of those deaths. A new study has looked at the frequency of binge drinking in relation to drinkers' own perceptions of their overall health status.

2 Jun 2010

First Edition: June 2, 2010

In today's news, insurance regulators fail to meet an early deadline for setting standards on premium spending rules within the new health law.

2 Jun 2010

AstraZeneca receives 2010 EcoLeadership Award for second consecutive year

AstraZeneca announced today it has received the 2010 EcoLeadership Award by the Alliance for Workplace Excellence for the second consecutive year. The EcoLeadership Award recognizes companies that demonstrate their commitment to environmental sustainability practices such as energy efficiency, waste minimization and water conservation.

2 Jun 2010

SAGES issues new practice guideline for surgical treatment of GERD

BARRX Medical Inc., a leader in the development of minimally invasive medical devices designed to remove precancerous tissue from within the gastrointestinal tract, reported today that the Society of American Gastrointestinal and Endoscopic Surgeons has issued a new practice guideline for the surgical treatment of gastroesophageal reflux disease. Left untreated, reflux of stomach contents such as acid and bile into the esophagus in GERD patients often leads to injury and chronic inflammation of the lining of the esophagus.

2 Jun 2010

SOFAR licenses Immersion's TouchSense haptics technology for use in ALF-X telesurgical robot system

Immersion Corporation, the leading developer and licensor of haptics technology, today announced that SOFAR S.p.A., a leading Italian manufacturer of medical devices for minimally invasive surgery, has obtained a license to Immersion's TouchSense haptics technology for use in its ALF-X (Advanced Laparoscopy through Force Reflection) telesurgical robot system.

2 Jun 2010

Updates in Surgery, the official journal of SIC to be published by Springer in English

From June 2010, Springer will publish Updates in Surgery, the official journal of the Italian Society of Surgery. The journal, previously a bilingual Italian-English publication, is now published four times a year in English only. The content will be available in print for the society members and it will also be electronically available on Springer's platform www.springerlink.com.

2 Jun 2010

Raptor Pharmaceutical acquires exclusive license to intellectual property for Huntington's Disease treatment

Raptor Pharmaceutical Corp., announced that the Company has acquired an exclusive worldwide license to intellectual property related to the potential treatment of Huntington's Disease from the Weizmann Institute of Science in Israel and Niigata University in Japan. In addition, Raptor has added Professor Lawrence Steinman, M.D., an inventor on the Weizmann patent, to its Advisory Board.

2 Jun 2010

Intimate partners can have important influence on another's substance use: Study

A new study of young people in the two years after high school finds that those in romantic relationships are less likely than their peers to report heavy drinking and marijuana use.

2 Jun 2010

Illumina commences shipment of new HumanOmni2.5-Quad DNA Analysis BeadChip microarray

Illumina, Inc. today announced that it has begun shipping its new HumanOmni2.5-Quad DNA Analysis BeadChip (Omni2.5). This microarray contains millions of newly discovered genome-wide common and rare variants from the 1,000 Genomes Project (1kGP), selected to maximize its ability to detect new associations.

From Illumina, Inc. 2 Jun 2010

Park Place International to unveil new website in conjunction with MUSE 2010 conference

Park Place International, a provider of comprehensive professional services for MEDITECH clients, is pleased to unveil its new company website in conjunction with the MUSE 2010 conference. Park Place International has been delivering accredited technology lifecycle services to the MEDITECH community for 20 years.

2 Jun 2010

Genes influence AIAA side effect in breast cancer survivors

Aromatase inhibitor-associated arthralgia (AIAA) is a major side effect in breast cancer survivors, producing joint pain so severe that as many as ten percent of women discontinue their therapy prematurely while undergoing treatment with these lifesaving drugs.

2 Jun 2010

FC Barcelona agrees to make Herbalife its Official Nutrition Sponsor

Herbalife Ltd. announced a three-year, multi-million dollar agreement with FC Barcelona to make Herbalife the club's Official Nutrition Sponsor. At the same time, Leo Messi has agreed to a personal sponsorship agreement.

2 Jun 2010

ZymoGenetics commences Phase 2B study of PEG-Interferon lambda in hepatitis C

ZymoGenetics, Inc. today announced the initiation of the second part of a Phase 2 clinical trial with PEG-Interferon lambda (IL-29) and ribavirin in treatment-naïve patients with chronic hepatitis C virus (HCV) infection. ZymoGenetics is developing the investigational compound PEG-Interferon lambda in collaboration with Bristol-Myers Squibb Company.

2 Jun 2010

Predictive biomarker for patients with NSCLC

The era of one-size-fits-all medicine will eventually be history; after all it is no news that drugs and treatments do not work the same for everyone. For patients with nonsmall cell lung cancer, a lung cancer that kills approximately 1 million people annually, the treatment currently available is basically the same for all patients, despite the fact that some patients may respond to treatment while others may not.

2 Jun 2010

Ablexis to advance transgenic mouse platform for antibody discovery with $12M Series A financing

Ablexis, LLC, a biotechnology company dedicated to developing an innovative, next-generation platform for antibody drug discovery, announced today that it has completed a $12 million Series A financing. The round was led by Third Rock Ventures and included Pfizer Venture Investments. Proceeds from the financing will be used to continue advancing Ablexis' proprietary AlivaMab Mouse transgenic mouse platform for the discovery of human therapeutic antibodies.

2 Jun 2010

Alexion Pharmaceuticals plans to launch Soliris in Japan for patients with PNH

Alexion Pharmaceuticals, Inc. and Alexion Pharma International Sàrl today announced that the launch of Soliris (eculizumab) as a treatment for patients with PNH in Japan will begin in the third quarter of 2010, approximately three months earlier than previously expected.

2 Jun 2010

Medical News

ENMD-2076 demonstrates antitumor activity against murine xenograft models of CRC: Study

Biomoda, Obio sign MOU to establish CLIA-certified clinical laboratory in Ohio

Asuragen obtains license to integrate BRAF V600E mutation sequence into its molecular diagnostic products

Constellation Pharmaceuticals raises $22 million in Series B financing round

CDC data shows frequent binge drinkers more likely to report suboptimal self-rated health

First Edition: June 2, 2010

AstraZeneca receives 2010 EcoLeadership Award for second consecutive year

SAGES issues new practice guideline for surgical treatment of GERD

SOFAR licenses Immersion's TouchSense haptics technology for use in ALF-X telesurgical robot system

Updates in Surgery, the official journal of SIC to be published by Springer in English

Raptor Pharmaceutical acquires exclusive license to intellectual property for Huntington's Disease treatment

Intimate partners can have important influence on another's substance use: Study

Illumina commences shipment of new HumanOmni2.5-Quad DNA Analysis BeadChip microarray

Park Place International to unveil new website in conjunction with MUSE 2010 conference

Genes influence AIAA side effect in breast cancer survivors

FC Barcelona agrees to make Herbalife its Official Nutrition Sponsor

ZymoGenetics commences Phase 2B study of PEG-Interferon lambda in hepatitis C

Predictive biomarker for patients with NSCLC

Ablexis to advance transgenic mouse platform for antibody discovery with $12M Series A financing

Alexion Pharmaceuticals plans to launch Soliris in Japan for patients with PNH

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Latest News